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Abstract 
Background: Cancer immunotherapy can be potentiated by conditioning regimens such as cyclophosphamide, 
which reduces the level of regulatory T cells (tregs). However, myeloid suppressive cells are still remaining. Accordingly 
to previous reports, gemcitabine improves immune status of cancer patients. In this study, the role of gemcitabine 
was further explored to map its immunological target cells and molecules in patients with pancreatic cancer.
Methods: Patient blood was investigated by flow cytometry and cytokine arrays at different time points during 
gemcitabine treatment.
Results: The patients had elevated myeloid-derived suppressor cells (MDSCs), and Tregs at diagnosis. Myeloid cells 
were in general decreased by gemcitabine. The granulocytic MDSCs were significantly reduced while monocytic 
MDSCs were not affected. In vitro, monocytes responding to IL-6 by STAT3 phosphorylation were prevented to 
respond in gemcitabine medium. However, gemcitabine could not prevent STAT3 phosphorylation in IL-6-treated 
tumor cell lines. TGFβ-1 was significantly reduced after only one treatment and continued to decrease. At the same 
time, the effector T cell:Treg ratio was increased and the effector T cells had full proliferative capacity during the gem-
citabine cycle. However, after a resting period, the level of suppressor cells and TGFβ-1 had been restored showing the 
importance of continuous conditioning.
Conclusions: Gemcitabine regulates the immune system in patients with pancreatic cancer including MDSCs, Tregs 
and molecules such as TGFβ-1 but does not hamper the ability of effector lymphocytes to expand to stimuli. Hence, it 
may be of high interest to use gemcitabine as a conditioning strategy together with immunotherapy.
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Background
Pancreatic cancer is a devastating disease with an inci-
dence rate that advances at a particularly high rate in 
industrialized countries. The commonly late diagnosis 
at an advanced stage and the resistance to conventional 
therapies make pancreatic cancer one of the most deadly 
cancers worldwide [1]. Pancreatic tumors have a char-
acteristic immunosuppressive tumor microenvironment 
with dense stroma formation mediated by pancre-
atic stellate cells (PSCs). These cells get activated dur-
ing inflammation by growth factors like transforming 
growth factor beta-1 (TGFβ-1), fibroblast growth fac-
tor and platelet-derived growth factor. Once activated, 
PSCs secrete collagen abundantly, which contributes to 
the dense and fibrous stroma formation. This process 
leads to the impaired vascularization and formation 
of the drug delivery barrier seen in pancreatic can-
cer [2]. Furthermore, PSCs can directly interact with 
immune cells as they secrete interleukin (IL)-6 and 
thus stimulate the recruitment of myeloid-derived sup-
pressor cells (MDSCs) into the tumor microenviron-
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heterogeneous cell population of immature myeloid cells 
elevated in many cancers. MDSCs typically express the 
myeloid markers CD11b and CD33, but not the MHC 
class II molecule HLA-DR. They can be further subdi-
vided into granulocytic or monocytic MDSCs based on 
CD14 expression [4]. MDSCs are expanded and acti-
vated in response to a variety of inflammatory factors 
that are secreted directly by tumor cells, PSCs and other 
adjacent immune cells. These factors include granulo-
cyte–macrophage colony-stimulating factor (GM-CSF), 
TGFβ, interferon-gamma (IFN-γ) and a variety of inter-
leukins (IL-1β, IL-6, IL-10) [5]. MDSCs are able to sup-
press the immune response mainly in two ways: They 
either directly suppress T cell responses or induce the 
expansion of regulatory T cells (Tregs). Both MDSCs 
and Tregs are present in early and late stage pancreatic 
tumors, whereas tumor-specific T cells are low in num-
bers and have an impaired activation [6]. Moreover, 
MDSCs and Tregs were also found to be positively and 
negatively correlated with tumor progression and overall 
survival, respectively [7, 8].
Immunotherapy is becoming a corner stone in cancer 
treatment with the introduction of checkpoint block-
ade antibodies [9]. However, significant responses in 
pancreatic cancer have thus far been absent [10, 11]. 
The severely immunosuppressive state combined with 
the dense profile of pancreatic lesions likely need to be 
combated to achieve an adequate anti-tumor immune 
response. In animal models, checkpoint blockade given 
together with other activating immunotherapy as well as 
gemcitabine  ±  paclitaxel have shown promising results 
[12, 13]. Gemcitabine is the standard of care for pan-
creatic cancer patients [14] and was shown to inhibit 
suppressor cells in these patients [15]. Therefore, combi-
nation of gemcitabine with immunotherapy in pancreatic 
cancer and potentially also in other indications may be of 
high interest. Hence, in this study we further explore the 
potential role of gemcitabine as a conditioning treatment 
to immunotherapy by evaluating the level of suppres-
sor cells and their cytokines as well as the effector cell 




Blood samples were collected from patients diagnosed 
with pancreatic adenocarcinoma undergoing gem-
citabine treatment at Uppsala University Hospital in 
accordance with ethical permit DNr: 2013/173. Gemcit-
abine is given at day 1, 8 and 15 in a 28-day cycle. Blood 
samples were collected just prior to gemcitabine infusion 
at day 1, 8, and 15 as well as after the resting phase (day 
29) prior to the initiation of the next gemcitabine cycle. 
Blood taken in heparinized tubes was Ficoll-Paque gradi-
ent (GE Health Care, Little Chalfont, UK) separated and 
the peripheral mononuclear cells (PBMCs) were frozen at 
−80  °C. Plasma was collected from EDTA coated tubes 
and frozen at −80  °C. PBMCs from healthy controls 
(HCs) were collected from the blood bank at Uppsala 
University Hospital.
Flow cytometry
Phenotypic expression of PBMCs from pancreatic can-
cer patients and HCs were evaluated with flow cytom-
etry. In short, PBMCs were thawed and FcR blocking 
reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) 
was added to block unspecific binding for 10 min. Cells 
were then incubated with specific antibodies and iso-
type control for 30  min at 4  °C before suspended in 
0.5  % bovine serum albumin (BSA) (Sigma-Aldrich, St. 
Louis, USA) in 1× PBS. Cells stained for FOXP3 were 
fixed and permeabilized with FOXP3 fix/perm buffer 
set from Biolegend (San Diego, CA, USA) according to 
manufacturer’s protocol. Antibodies used: αCD11b PE/
Cy7 (clone ICRF44), αCD14 APC/Cy7 (clone HCD14), 
αCD33 PE (clone WM53), αCD40 APC (clone HB14), 
αHLA DR PerCP (clone L243), αPD-L1 Brilliant Vio-
let 421 (clone 29E.2A3), αCD3 FITC (clone UCHT-1), 
αCD16 PE/Cy7 (clone 3G8), αCD56 APC (clone HCD56), 
αCD4 PerCP (clone OKT4), αCD127 Brilliant Violet 421 
(cloneA019D5), αFOXP3 Alexa Flour 649 (clone 206D), 
αCD107a PE (clone H4A3), mouse IgG1κ PE (clone 
MOPC-21), mouse IgG1κ APC (clone MOPC-21), mouse 
IgG1κ FITC (clone MOPC-21), mouse IgG2a PerCP 
(clone MOPC-173), mouse IgG2bκ Brilliant Violet 421 
(clone MPC-11), mouse IgG1κ Alexa Flour 649 (clone 
MOPC-21), all purchased from Biolegend, and αCD86 
FITC (clone 2331) purchased from BD Bioscience (San 
Jose, CA, USA). Cells were run in a BD FACS Canto II 
(BD Biosciences) and results were evaluated in Flow Jo 
(Tree Star, Ashland, OR, USA). For gating strategies see 
Additional file 1.
STAT3 assay
Pancreatic cell lines MiaPaCa2 and Panc01, or donor-
derived monocytes from two healthy donor buffy coats 
(Uppsala University Blood Central) were cultured ±IL-6 
(10  ng/mL; Biolegend) and/or ±gemcitabine (20uM; 
Sigma-Aldrich, St. Louis, MO, USA) for 20 min and ana-
lyzed for STAT3 phosphorylation using Bio-plex Pro 
p-STAT 3 (Tyr705) kit from Bio-Rad (Hercules, CA, 
USA). Samples were run in triplicates. The experiment 
was repeated using a 4-h prestimulation with gemcit-
abine prior to IL-6 addition with similar results.
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Proliferation assay
The proliferation capacity of the PBMCs from pancre-
atic patients and HCs was evaluated with Alarmar Blue 
assay (Life Technologies™ Carlsbad, CA, USA). In short, 
PBMCs were thawed and adjusted to a concentration of 
0.5  ×  106/mL in Roswell Park Memorial Institute 1640 
medium supplement with 10  % fetal bovine serum and 
1  % Penicillin Streptomycin from Life Technologies™. 
100,000 cells together with 100  IU/mL of IL-2 (Pro-
leukein, Novartis, Basel, Switzerland) were added into 
96-well plates pre-coated with 1 µg/mL of OKT-3 (Biole-
gend). Measurements were taken at 0, 24, 48, 72 and 96 h 
at 570 nm and 595 nm as background.
Cytokine analysis
Plasma from the pancreatic adenocarcinoma patients 
were evaluated by ELISA for expression of TGF-β1 (Dia-
clone, Besançon cedex, France), Arginase-1 (Hycult® bio-
tech, Plymouth Meeting, PA, USA), and Myeloperoxidase 
(Biolegend). Mesco Scale Discovery V-plex (Rockville, 
MD, USA) was used for detection of IL-1β, IL-6, IL-8, 
IL-10, and TNFα.
Statistical analysis
Graphpad Prism (Graphpad Software Inc. La Jolla, CA, 
USA) was used for determining statistical significance. 
Differences between HCs and patients were assessed 
by unpaired t test with Welch’s correction. Wilcoxon 
matched-pairs signed-rank test was performed to evalu-
ate differences between the patient samples of the dis-
tinct days. STAT3 analyses were done using one-way 
ANOVA for multi-comparison testing.
Results
Patient characteristics
In this study, ten patients diagnosed with pancreatic ade-
nocarcinoma were enrolled to receive gemcitabine treat-
ment as their standard of care and were investigated for 
their immune profile before and at different time points 
post treatment initiation. The patient group consisted of 
six men and four women, with a mean age at study entry 
of 70.3 ± 6 years and 71.3 ± 6.1 years, respectively (Addi-
tional file 2). Three patients had their tumor removed by 
surgery and then received adjuvant gemcitabine treat-
ment. Seven patients received gemcitabine as palliative 
care without prior surgery, of which five patients were 
treated for locally advanced disease and two patients for 
metastasized disease. Additional file 2: Table S1 displays 
the clinical characteristics of each patient. The patients 
were treated with gemcitabine (1000 mg/m2) once weekly 
for 3 weeks (day 1, 8, 15) followed by a resting phase for 
2 weeks after the third treatment (Fig. 1a).
Gemcitabine reduces myeloid cells including granulocytic 
myeloid‑derived suppressor cells
Gemcitabine is known to affect myeloid cells. In our 
study, the level of CD11b+CD14+ monocytes was simi-
lar between the patients and healthy controls prior to 
treatment (day 1). After the first gemcitabine administra-
tion, the monocytes were significantly reduced but were 
restored after the resting period (Fig. 1b). CD86 was sig-
nificantly higher expressed on patients’ monocytes at day 
1 compared to controls. Nevertheless, the expression of 
CD86 (Fig. 1c) was decreased after treatment with gem-
citabine but increased after the resting week. A simi-
lar trend was observed for the expression of the MHC 
class II molecule HLA-DR (Fig. 1d). In contrast, patient 
monocytes exhibited no significant change of CD40 
expression (Fig. 1e), while expression of PD-L1 (Fig. 1f ) 
was significantly increased after the first gemcitabine 
administration.
MDSCs are generally classified as either belonging 
to the granulocytic or monocytic lineage. In humans, 
MDSCs are mostly referred to as the granulocytic sub-
set, meaning that they do not express CD14 but express 
CD11b and CD33 and lack the expression of the MHC 
class II molecule HLA-DR [5]. Thus, we defined the 
granulocytic subset as CD11b+CD14−CD33+HLA-DR− 
and also investigated a monocytic subset (CD11b+ 
CD14+CD33+HLA-DR−). Both the granulocytic (Fig. 1g) 
and monocytic (Fig.  1h) MDSCs were significantly ele-
vated in the patient population compared to healthy 
controls before treatment. After the first treatment, 
the granulocytic MDSCs were significantly decreased 
to a level similar to controls. However, after the resting 
period, the granulocytic MDSCs were increased again. 
Despite the reduction of granulocytic MDSCs, gem-
citabine did not affect monocytic MDSCs. The patients 
with the shortest survival had significantly higher levels 
of monocytic MDSCs compared to patients who survived 
more than 1 year.
The effector T cell:T regulatory cell ratio is shifted 
by gemcitabine
Tregs, defined as CD3+CD4+CD127−FoxP3+ cells [16], 
were significantly elevated in patients before treatment 
compared to healthy individuals. Gemcitabine treat-
ment reduced the mean Tregs number modestly but 
significantly, since almost all patients showed a decrease 
in Tregs from baseline. Nevertheless, the Treg level in 
patients was still elevated in comparison to the healthy 
controls at all time points (Fig.  2a). Lymphocytes are 
generally not affected by gemcitabine. However, the ratio 
between effector T cells and Tregs was elevated at day 
15, indicating a reduction of Tregs and/or an increase 
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of effector T cells subsequent to gemcitabine therapy 
(Fig. 2b).
TGFβ‑1 is reduced by continuous gemcitabine 
administration
To further evaluate the effect of gemcitabine on the 
patients’ immunosuppressive status, plasma samples 
were assessed for inflammatory molecules (Fig.  3). The 
mean values of arginase-1, myeloperoxidase (MPO), 
IL-6, IL-8, IL-10 and TNFα did not change consider-
ably throughout the first cycle of gemcitabine treatment 
even if several individual patients had decreased Argin-
ase-1 and MPO post gemcitabine initiation. TGFβ-1 was 
significantly reduced by gemcitabine in all patients. The 
level of TGFβ-1 decreased already after the first admin-
istration and was even further reduced at day 15. Despite 
Fig. 1 Study outline and the effect of gemcitabine on myeloid cells. a Ten pancreatic cancer patients were enrolled (E) and sampled during the 
first cycle of gemcitabine treatment (G), where gemcitabine was given once weekly for three weeks, followed by a resting period. Blood samples 
(S) were collected at day 1, 8, 15 and 29 always before gemcitabine was given that day. Patient and healthy control (HC) samples were stained for 
CD14+CD11b+ monocytes (b) and CD86 (c), HLA-DR (d), CD40 (e) and PD-L1 expression (f). Samples were also stained for granulocytic (g) and 
monocytic MDSCs (h), defined as CD11b+CD14− CD33+ HLA-DR− and CD11b+ CD14+ CD33+ HLA-DR-, respectively. Samples were analyzed by 
flow cytometry. Statistical differences between HCs and patients or between sample days were assessed by unpaired t-test with Welch’s correction 
or Wilcoxon matched-pairs signed-rank test, respectively (*P < 0.05, **P < 0.01, ***P < 0.001)
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this immense reduction, TGFβ-1 was restored to the ini-
tial level after the resting period (day 29) (Fig. 3c). A sig-
nificant increase after the resting period was observed in 
IL-1β. However, overall IL-1β was very low (Fig. 3d).
The effect of gemcitabine on STAT3
STAT3 is involved in the regulation of myeloid cells 
toward a more suppressive phenotype and since the mye-
loid population was affected by gemcitabine the level of 
phosphorylated STAT3 was evaluated in tumor cells and 
monocytes in vitro in response to gemcitabine. To induce 
STAT3 phosphorylation tumor cells and monocytes were 
stimulated by IL-6, cultured with or without gemcit-
abine and then analyzed by using Bio-plex Pro p-STAT3 
(Tyr705) kit (Fig.  4). IL6 induced STAT3 phosphoryla-
tion in both MiaPaCa2 and Panc01 pancreatic cancer cell 
lines, but only in one of the two healthy donor-derived 
monocytes. In both tumor cell lines, the addition of gem-
citabine to the IL-6-stimulated cells did not decrease 
STAT3 phosphorylation. However, in the monocyte cul-
ture that initially responded to IL-6, gemcitabine pre-
vented STAT3 phosphorylation while the other donor 
showed no difference to gemcitabine.
Gemcitabine does not affect the T cell proliferative 
capacity
In order to exclude that gemcitabine treatment depletes 
T and NK cells, which are crucial for anti-tumor immune 
responses, their presence was investigated before (day 
1) and at different time points post gemcitabine treat-
ment initiation (day 8, 15, 29). T cells were gated as 
CD3+ lymphocytes and further divided into T helper 
cells (CD3+CD4+) and cytotoxic T cells (CD3+CD4−). At 
day 1, both T cells and NK cells were at the same level 
as in healthy controls (Fig. 5a, c, e, g). Throughout gem-
citabine treatment, CD3+ lymphocytes were significantly 
increased from day 1 to day 15. The level of T helper 
cells declined after the resting period while the cytotoxic 
T cells were increased (Fig. 5c, e). Nevertheless, both T 
helper cells and cytotoxic T cells had a decreased base 
level of CD107a, which is a marker of cytolytic activity, 
compared to T cells from healthy controls. However, 
CD107a expression remained stable during gemcit-
abine treatments (Fig.  5b, d, f ). There was a tendency 
of increased CD107a expression in the cytotoxic T cell 
population at day 29 but it did not reach significance. 
NK cells were gated as CD3−CD56+CD16+ lympho-
cytes. The level of NK cells in the patients was similar to 
healthy controls (Fig.  5g). NK cells seemed more sensi-
tive to gemcitabine than T cells, and the NK cell level was 
reduced in most patients from day 1 to day 15.
Finally, the capacity of the T cells to proliferate was 
evaluated to ensure that the patients’ T cells are able to 
respond to stimuli during gemcitabine treatment. PBMCs 
from both patients and healthy controls were stimulated 
with anti-CD3 (OKT-3) and IL-2 and their proliferative 
response was evaluated by Alamar Blue proliferation kit 
over time. The patients’ T cells responded as good as T 
cells from healthy controls at any time point after gem-
citabine initiation. In fact, in comparison to the controls, 
the patients’ T cells proliferated slightly better and this 
was most evident in patient samples from day 29 (Fig. 6).
Fig. 2 The effect of gemcitabine on regulatory T cells (Tregs). Ten pancreatic cancer patients were sampled during the first cycle of gemcitabine 
treatment, where gemcitabine was given once weekly for 3 weeks, followed by a resting period. Blood samples were collected at day 1, 8, 15 
and 29 always before gemcitabine was given that day. Patient and healthy control (HC) samples were stained for tregs, which were defined as 
CD3+CD4+CD127−FoxP3+. Samples were analyzed by flow cytometry. Statistical differences between HCs and patients or between sample 
days were assessed by unpaired t-test with Welch’s correction or Wilcoxon matched-pairs signed-rank test, respectively (*P < 0.05, **P < 0.01, 
***P < 0.001)
Page 6 of 12Eriksson et al. J Transl Med  (2016) 14:282 
Fig. 3 The effect of gemcitabine on immunomodulatory plasma proteins. Ten pancreatic cancer patients were sampled during the first cycle of 
gemcitabine treatment, where gemcitabine was given once weekly for 3 weeks, followed by a resting period. Blood samples were collected at day 
1, 8, 15 and 29 always before gemcitabine was given that day. Plasma levels of Arginase-1, MPO and TGFβ-1 were evaluated by ELISA (a–c) and MDS 
multiplex analysis was performed for determining plasma levels of IL-1β, IL-6, IL-8, IL-10 and TNFα (d–h). Concentrations are displayed in ng/mL or 
pg/mL and statistical differences were assessed by Wilcoxon matched-pairs signed-rank test (*P < 0.05, ** P < 0.01)
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Discussion
Despite other advances in cancer research, the poor 
prognosis for pancreatic cancer patients has not changed 
during the last few decades and life expectancy remains 
low [17]. Recently, immunotherapy has been in the lime-
light of cancer research, where impressive effects have 
been seen using immune checkpoint antibody blockade 
treatment in various malignancies and the treatment has 
been established in melanoma patients [18]. Such anti-
bodies improve T cell function by blocking CTLA-4 or 
PD-1/PD-L1 signaling which releases the anergic T cells 
to become active participants in the anti-tumor immune 
response [19]. In a phase 2 trial by Royal et al., the effect 
of the monoclonal anti-CTLA-4 antibody ipilimumab 
was studied in patients with advanced pancreatic cancer. 
Only one patient out of 27 showed a delayed response to 
ipilimumab, indicating that this strategy is not of signifi-
cant value for this indication [11]. However, animal data 
suggests that it may be possible to circumvent check-
point blockade resistance by adding immunostimulatory 
agents. For example, checkpoint blockade in combina-
tion with agonistic CD40 antibodies plus gemcitabine 
and nab-paclitaxel showed promising data in mice [13]. 
In the experimental models, chemotherapy improved the 
results on tumor growth. Studies are ongoing to explore 
if immunotherapy successfully can be given simultane-
ously to the standard of care gemcitabine in patients with 
pancreatic cancer (http://www.clinicaltrials.gov). The 
Fig. 4 STAT3 phosphorylation post IL-6 and gemcitabine treatment. Pancreatic cell lines MiaPaCa2 (a) and Panc01 (b) or healthy donor derived 
monocytes from donor 1 (c) or donor 2 (d) were cultured ±IL-6 (10 ng/ml) and/or ±gemcitabine (20 μM) and analyzed for STAT3 phosphorylation 
using Bio-plex Pro p-STAT3 (Tyr705) kit. Samples were run in triplicates. Statistical differences were calculated using one-way ANOVA multicompari-
son test at a 95 % confidence interval. Significant differences are labeled with an asterisk
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Fig. 5 The effect of gemcitabine on effector lymphocytes. Ten pancreatic cancer patients were sampled during the first cycle of gemcitabine 
treatment, where gemcitabine was given once weekly for 3 weeks, followed by a resting period. Blood samples were collected at day 1, 8, 15 and 
29 always before gemcitabine was given that day. Patient and healthy control (HC) samples were stained for CD3+ lymphocytes, CD4+ and CD4− T 
cells (CD8+) and NK cells (CD56+CD16+). T cell activation was assessed by CD107a expression and the samples were analyzed by flow cytometry. 
Statistical differences between HCs and patients or between sample days were assessed by unpaired t-test with Welch’s correction or Wilcoxon 
matched-pairs signed-rank test, respectively (*P < 0.05, ****P < 0.0001)
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doses, the route of administration and effect over time is 
not comparable in mice and man.
In this study, we investigated the immunomodulatory 
properties of gemcitabine chemotherapy in ten pan-
creatic cancer patients. Even if the cohort was small, 
the results were consistent showing the same trend in 
most patients and, hence, small variations. Myelosup-
pression is a well-known side effect of chemotherapies 
[20]. Thus, also we observed that myeloid cells includ-
ing MDSCs were reduced by gemcitabine treatment. 
Chikamatsu et  al. proposed that CD86 and PD-L1 
are implicated in mediating the suppressive effects of 
MDSCs [21]. We found that gemcitabine treatment 
could reduce CD86, but not PD-L1 expression, which 
instead increased subsequently to the first gemcitabine 
administration. Hence, it might be of interest to com-
bine gemcitabine chemotherapy with PD-1/PD-L1 block-
ade. Gemcitabine treatment also significantly reduced 
CD11b+CD14−CD33+HLA-DR− granulocytic MDSCs, 
although this reduction was reversed after the resting 
phase where no gemcitabine was given. This demon-
strates the need to administer gemcitabine continuously 
to achieve a durable effect on the levels of MDSCs. A 
combination of gemcitabine and capecitabine was previ-
ously shown to reduce Lin-DR−CD11b+ MDSCs in 42 % 
of the studied pancreatic cancer patients, but this reduc-
tion did not reach significance [22]. In our study, mono-
cytic MDSCs were the most prevalent in the peripheral 
blood, but this subset was not significantly reduced by 
gemcitabine. Also, these cells were present at higher lev-
els in patients who survived less than 1  year. Opposed 
to this, Khaled et  al. only found granulocytic MDSCs 
(Lin−HLA-DR−CD33+CD11b+CD15+), but not mono-
cytic MDSCs (Lin−HLA-DR−CD14+) to be elevated 
in pancreatic cancer patients [23]. These contradictory 
results might be explained by the heterogeneity of MDSC 
markers used to define the different subsets.
Despite the reduction of granulocytic MDSCs subse-
quent to gemcitabine treatment, we found no signifi-
cant change of the MDSC effector molecules arginase-1 
Fig. 6 Proliferative capacity of T cells post gemcitabine. Ten pancreatic cancer patients were sampled during the first cycle of gemcitabine treat-
ment, where gemcitabine was given once weekly for 3 weeks, followed by a resting period. Blood samples were collected at day 1, 8, 15 and 29 
always before gemcitabine was given that day. The capacity of T cells to proliferate in response to CD3 antibody and IL-2 stimulation was assessed 
by Alarmar Blue assay. Measurements were taken at 0, 24, 48, and 72 h at 570 and 595 nm. Grey lines Healthy controls (HC), Black lines patients. Statis-
tical differences between HCs and patients were assessed by unpaired t-test with Welch’s correction (*P < 0.05, **P < 0.01)
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and MPO. However, values in several individual patients 
decreased even if that did not significantly alter the 
whole cohort. A decrease of these markers along with a 
decrease of MDSCs has been achieved with other anti-
cancer drugs, for example with tyrosine kinase inhibi-
tors in myeloid leukemia patients [24]. Nevertheless, in 
individual patients we did see a decrease of these inhibi-
tors. A study by Khaled et al. showed that only granulo-
cytic MDSCs expressed arginase-1 [23] and it has been 
proposed that monocytic MDSCs exert their suppres-
sive function through inducible nitric oxide synthase 
[5]. In contrast, Filipazzi et al. demonstrated that mono-
cytic CD14+HLA-DR−/lo cells mediated their suppres-
sive activity via TGFβ release [25]. In the current study, 
we found a profound effect of gemcitabine treatment on 
TGFβ-1 plasma level. TGFβ-1 was reduced subsequent 
to each administration, but was increased again after the 
resting period. In a study in pancreatic cancer patients 
by Vizio et al., TGFβ-1 was not significantly reduced by 
gemcitabine. However, these patients had overall much 
lower levels of TGFβ-1 [15]. This and different sampling 
time points might explain the contrasting results. In 
patients with non-small cell lung cancer, treatment with 
gemcitabine plus cisplatin significantly reduced serum 
TGF-β1 levels in patients who had a complete or partial 
response to chemotherapy [26].
The strong inhibitory effect of gemcitabine on TGFβ-1 
may be explained by regulation by STAT3. STAT3 is 
a transcription factor that plays a crucial role in many 
essential processes of the cell, including survival and pro-
liferation [27]. Moreover, STAT3 signaling is particularly 
important in the expansion and function of MDSCs [5], 
in the conversion of naïve CD4+ T cells to Tregs [28] and 
also in the induction of TGFβ-1 [29]. In a study by Tang 
et al., gemcitabine was found to inhibit several genes that 
are regulated by STAT3, which suggests that gemcitabine, 
might indeed target STAT3 and its downstream signaling 
[30]. In addition, a connection between gemcitabine and 
STAT3 is plausible as inhibition of STAT3 was observed 
to enhance the response to gemcitabine in a pancreatic 
cancer animal model [31]. Our results indicate that gem-
citabine may prevent STAT3 phosphorylation in myeloid 
cells while we did not see any significant difference in 
STAT3 phosphorylation upon gemcitabine treatment in 
pancreatic tumor cell lines. Hence, gemcitabine in clini-
cally relevant levels [32] does not likely target STAT3 
directly but may affect STAT3 phosphorylation by indi-
rect mechanisms in myeloid cells. Due to the different 
responses noted in different donors, such events may also 
be individual and highly time point dependent.
Gemcitabine is not in general known to affect the lym-
phocyte population. Nevertheless, we evaluated the level 
of Tregs and effector T cells in our patients. Tregs were 
elevated in our cohort at pretreatment and this has also 
been noted in other studies [33, 34]. Furthermore, Treg 
depletion by gemcitabine has previously been described 
both in tumor-bearing mice and in cancer patients [15, 
35, 36]. In our cohort of pancreatic cancer patients, 
gemcitabine reduced Treg levels modestly after two 
treatments. Nevertheless, gemcitabine did not hamper 
the function of effector T cells in our study. Rather, the 
effector to Treg ratio was increased and the proliferative 
capacity of effector T cells seemed higher in the patients 
compared to healthy controls, especially after complet-
ing the cycle of three gemcitabine doses. Correspond-
ingly, Plate et al. noted an increase in CD4+ T cells and 
an enhanced T cell function during gemcitabine therapy 
in pancreatic cancer patients [37]. In another study, in 
which pancreatic cancer patients were treated with gem-
citabine plus cisplatin, T cell function was not impaired 
[38]. The effect of gemcitabine on the lymphocytes is 
likely due to the reduction of immunosuppressive cells 
and TGFβ-1 rather than a direct effect on these cells.
Conclusions
In conclusion, gemcitabine decreases immunosuppres-
sive immune cell populations and reduces TGFβ-1 con-
siderably while sparing the function of effector T cells. 
Hence, conditioning treatment with gemcitabine along-
side of immunotherapy may be effective in pancreatic 
cancer patients for whom gemcitabine is golden stand-
ard, but possibly also in patients with other malignancies.
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